June 16, 2011
Oregon Health & Science University (OHSU) is the state’s only academic health center, and is among the state’s largest healthcare providers, educational institutions, research centers and employers. OHSU’s health and economic impacts are substantial, and while its activities are centered in the Portland metropolitan area, its impact reaches throughout the state.
June 16, 2011
The Oregon Bioscience Association is pleased to share industry updates, benchmarks, strategy and milestones in its 2010 Annual Report on Community, Collaboration and Commercialization. Throughout 2010, Oregon’s bioscience industry remained an economic bright spot. Despite this less than ideal environment, Oregon Bio made steady, measurable progress in building a solid financial foundation for future growth.
June 16, 2011
Oregon’s bioscience industry is recognized for its contributions to the health and well-being of our people, and there is a growing awareness of its positive impact on our state’s economy and on each community in which bioscience companies and institutions operate.
June 15, 2011
June 15, 2011
Washington State University
Spokane, WA
Read More
June 15, 2011
The Therapeutic Interchange Program (TIP) has developed a process allowing physicians and other prescribers to endorse the Washington State Preferred Drug List (PDL), and requires pharmacists to automatically substitute the preferred drug for non preferred drugs prescribed by these practitioners unless the prescription is for a refill of an antipsychotic, antidepressant, chemotherapy, antiretroviral, or immunosuppressive drug, in which case the pharmacist shall dispense the prescribed non preferred drug.
Read More.
June 15, 2011
This section contains the department’s rules for the endorsing practitioner therapeutic interchange program (TIP). TIP is established under RCW. The statutes require state-operated prescription drug programs to allow physicians and other prescribers to endorse a Washington preferred drug list (PDL) and, in most cases, requires pharmacists to automatically substitute a preferred, equivalent drug from the list.
Read More.
June 15, 2011
This section contains the department’s rules for the endorsing practitioner therapeutic interchange program (TIP). TIP is established under RCW. The statutes require state-operated prescription drug programs to allow physicians and other prescribers to endorse a Washington preferred drug list (PDL) and, in most cases, requires pharmacists to automatically substitute a preferred, equivalent drug from the list.
Read More.
June 14, 2011
By Brian Gormley
Wall Street Journal
U.S. pharmaceutical companies have long lived with generic rivals, and soon biotechnology concerns will face similar competition. Through the health-care reform law passed last year, Congress created a regulatory path for companies to introduce “biosimilars,” or nearly exact copies of biological drugs that have come off patent. Read More
May 20, 2011
By Jorgo Chatzimarkakis, PhD, member of European Parliament
The Health Care Blog
Around the world and now in the United States, there is a broadening discussion of how best to proceed down the path of approving and getting to market medicines called biosimilars. Biosimilars are non-identical copies of next generation medicines known as biologics. As the U.S. begins establishing new guidance for biosimilars, regulators and legislators should look to the European Union model on guidance policy and approve these important, often life-saving, drugs when they are proven to be safe for the patients they are intended to heal. Read More
May 20, 2011
By Jorgo Chatzimarkakis, PhD, member of European Parliament
The Health Care Blog
Around the world and now in the United States, there is a broadening discussion of how best to proceed down the path of approving and getting to market medicines called biosimilars. Biosimilars are non-identical copies of next generation medicines known as biologics. As the U.S. begins establishing new guidance for biosimilars, regulators and legislators should look to the European Union model on guidance policy and approve these important, often life-saving, drugs when they are proven to be safe for the patients they are intended to heal. Read More
